Skip to Main Content

Author Details

Ilsa Coleman
Fred Hutchinson Cancer Center
2001
137
49
PMIDPaper TitleJournal TitlePublished Year
37850574Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.J Pathol2024
37796107Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.Prostate2024
36399432Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.Cancer Discov2023
37559436Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.Prostate2023
37577653Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.bioRxiv2023
37823778Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.Cancer Res Commun2023
37973913SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer.Nat Commun2023
37725435Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.J Clin Invest2023
37533407Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.Mol Oncol2023
37352376Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.Cancer Res2023
37041154Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.Nat Commun2023
37440313LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.JCI Insight2023
36821396Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.JCI Insight2023
36779357Clinical, pathologic, and molecular features of amphicrine prostate cancer.Prostate2023
36337169Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.Cancer Res Commun2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
35552660Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2022
36511483Defining cellular population dynamics at single-cell resolution during prostate cancer progression.Elife2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
33471819Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.PLoS One2021
33792558The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.Endocr Relat Cancer2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
33564077Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.Oncogene2021
33586682MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.J Clin Invest2021
33724955Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.JCI Insight2021
33658518Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.Nat Commun2021
34877933Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.JCI Insight2021
34431104Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.J Pathol2021
34128479Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
34244513Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.Nat Commun2021
33958727Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.Oncogene2021
34145028BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.Clin Cancer Res2021
34312180RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.Cancer Res2021
34086042Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.JAMA Oncol2021
33998604Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
33199493Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.Clin Cancer Res2021
31227306Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.Eur Urol2020
34085047A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.Nat Cancer2020
31732520Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.Clin Cancer Res2020
31806771Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed Tumors.J Nucl Med2020
31806643Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.Clin Cancer Res2020
32068909A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.Prostate2020
32636317Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.Clin Cancer Res2020
32989253Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.Oncogene2020
32461304Targeting RET Kinase in Neuroendocrine Prostate Cancer.Mol Cancer Res2020
32460015Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.Cell Rep2020
32403054Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.Neoplasia2020
32197218Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN.Cancer Genet2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
30224545The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells.Mol Cancer Res2019
  • 1 - 50 of 137

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 21
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 2
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 1
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 14
Estelle Li
University of British Columbia
Career Start Year 2012
Number of shared co-authors 14
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 26
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 11
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 24
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 55
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 10
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 7
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 12
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 19
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 67
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 9
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 27
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 35
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 22
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 24
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 14
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 39
Nadia Boufaied
Research Institute of the McGill University Health Centre
Career Start Year 2000
Number of shared co-authors 21
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 10
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 56
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 9
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 42
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 35
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 20
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 16
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 27

Collaborators

Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 132
Colm Morrissey
Co-authored papers 54
Eva Corey
University of Washington School of Medicine
Co-authored papers 49
Lawrence D True
University of Washington School of Medicine
Co-authored papers 36
Robert L Vessella
University of Washington
Co-authored papers 30
Stephen R Plymate
University of Washington
Co-authored papers 22
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 20
Elahe A Mostaghel
University of Washington
Co-authored papers 18
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers 18
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 15
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 14
Beatrice S Knudsen
University of Utah
Co-authored papers 10
Daniel W Lin
Co-authored papers 10
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 8
Alexandra Corella
Fred Hutchinson Cancer Research Center
Co-authored papers 7
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 6
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 6
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 5
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 5
Yuzhuo Wang
University of British Columbia
Co-authored papers 4
Jianfeng Xu
Co-authored papers 4
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 4
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 4
Mark A Rubin
University of Bern
Co-authored papers 4
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 4
Martin E Gleave
University of British Columbia
Co-authored papers 4
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Release 1.2